We examined the prevalence of use and cost impact of DPP-4 inhibitors and GLP-1 receptor agonists in people with diabetes.
Frederick Brown, PharmD
Advertisement
Articles by Frederick Brown, PharmD
Based on American College of Rheumatology recommendations and novel emerging treatment options, the trend of increasing biologic use for rheumatoid arthritis is expected to continue.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Enlicitide, the First Oral PCSK9 Inhibitor for High Cholesterol
2
GLP-1s and Oncology: The Drug Interaction Clinicians Aren't Talking About
3
The Weekly Dose: Cyclosporiasis Outbreak Grows, AI-Powered Refills Pilot, and New FDA Approvals in Alzheimer Disease, Oncology
4
Improving Detection and Management of ATTR-CM Through Pharmacy Care
5